Novartis Secures Tabrecta Approval in China for METex14 NSCLC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...
Cancer
TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...
Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...
Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug...
Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio
Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR‑Spheres Y‑90 resin microsphere injection (brand name:...
Fosun Pharma Secures Foritinib Approval for ALK‑NSCLC Trials, Paving Way for Targeted Therapy
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its Class 1 chemical...
Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer
China‑based Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Phase III study of the HER2‑targeting antibody‑drug...
InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL
Shanghai‑based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September 8, 2025 that its Bruton’s tyrosine kinase...
Regenelead Secures NMPA Approval for RGL‑305 Cell Therapy in Advanced Malignant Tumors
On September 2, 2025, Shanghai‑based Regenelead announced that its internally developed cell‑therapy product RGL‑305 Injection received...
QuantumPharm XtalPi Secures Phase I Approval for PEP08, a Next‑Generation PRMT5 Inhibitor
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for...
TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced the first patient dose in an open‑label, multi‑center...
Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the China National Medical...
Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC
China’s Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced today that the first patient has...
Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) today announced that its novel...
Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. announced a landmark exclusive licensing collaboration with RADIANCE Biopharma....
Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has secured a pivotal regulatory milestone:...
Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Ltd...
Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the U.S. Food and Drug Administration...
Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) announced that it has entered into a license...